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Abstract. Adenoid cystic carcinoma (ACC) or ‘cylindroma’ is a 
malignant tumor that often occurs in the areas of the head and 
neck, affecting the secretory glands and the major and minor 
salivary glands. The present study describes a case of a patient 
who presented with a posterior tongue lesion. The case is of a 
71-year-old female with an asymptomatic volume growth of the 
posterior left tongue perceived 8 months prior, and neoplastic 
cells positive for c-kit. A computed tomography of the head and 
neck showed asymmetry of the base of the tongue, which was 
enlarged in the left portion. A physical examination revealed a 
nodule on the posterior left tongue of ~3 cm in diameter, while 
the cervical lymph node chain had a normal size and consistency. 
Surgical exeresis of the tongue lesion and cervical lymph node 
dissection were performed. Subsequent to surgical removal of 
the cancer cells and adjuvant radiotherapy, the patient showed 
excellent health, although the follow-up remains in progress. 
ACC, one of the most biologically destructive tumors of the 
head and neck, is locally aggressive and gives rise to distant 
metastases. The tongue is the place of origin in 3.4-17.1% of 
cases. The treatment for ACC consists of primary surgical resec-
tion with adjuvant radiotherapy. To prevent the risk for distant 
metastasis, it is necessary to remove the first echelon nodes and 
monitor the patient with a long-term follow-up.
Introduction
In 1859, Billroth (1) termed adenoid cystic carcinoma (ACC) 
as cylindroma, and then the lesion was designated as ACC by 
Foote and Frazell in 1953 (2). ACC is a malignant tumor that 
originates in the salivary glands and represents ~1-4% of all 
malignant neoplasms of the head and neck and ≤5-15% of all 
malignant salivary gland neoplasms (3-5). It constitutes ~29.6% 
of minor salivary gland tumors (3), and the most common minor 
salivary gland site is the hard palate, followed by the base of 
the tongue (4.4%) (6-9). ACC is characterized by slow growth, 
local recurrence, perineural invasion and potential to produce 
distant metastases, mainly to the lungs and bones (3,6). The 
peak incidence occurs predominantly among females between 
the 5th and 7th decades of life (3,10). The current study presents 
a rare case of a 71-year-old female patient with a c-kit positive 
posterior tongue ACC treated with surgery and adjuvant radio-
therapy. The patient provided written informed consent.
Case report
A 71-year-old female presented at the ‘Federico II’ University 
Hospital (Naples, Italy) with an asymptomatic volume growth 
on the posterior left tongue, perceived 8 months previously. 
The patient did not have a history of smoking or alcohol 
consumption, and had an insignificant past medical history, 
with the exception of type II diabetes mellitus treated with 
oral hypoglycemic agents. The clinical examination revealed 
a nodule on the posterior left tongue of ~3 cm in diameter with 
a similar color to the buccal mucosa, while the cervical lymph 
node chain had a normal size and consistency. A computed 
tomography of the head and neck performed with administra-
tion of contrast medium showed asymmetry of the base of the 
tongue, enlarged in the left portion, without visibility of areas 
of densitometric alteration, and a few small lateral cervical 
lymph nodes of ~1 cm in diameter bilaterally. A transoral 
exeresis of the tongue lesion emptying cervical lymph nodes 
at levels I-III ipsilateral to the tumor was performed. During 
the intervention, a tracheotomy was carried out to ensure 
breathing, which could be compromised by a postoperative 
edema of the tongue, and also left lingual artery ligation, to 
reduce bleeding. Histopathological analysis demonstrated a 
diffuse infiltration by ACC, cribriform subtype; the tumor 
was absent on the margins of excision and the neoplastic 
cells were focally positive to immunohistochemical staining 
for c-kit. All lymph nodes resulted as reactive. A nasogastric 
tube was removed 10 days after surgery. 
The patient then underwent postoperative radiotherapy 
and is currently under follow-up, demonstrating good health 
12 months after the intervention.
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Discussion
ACC is one of the most biologically harmful and incalculable 
tumors of the head and neck (5), is locally aggressive and is 
characterized by infiltrative growth and perineural spread, 
leading to high recurrence levels, despite aggressive surgical 
resection and late metastasis, with patient mortality between 
10 and 20 years after the initial treatment (5,9,11,12). The most 
common site of distant metastases is the lung, although bone, 
liver, kidney and prostate have also been reported (12).
ACC of the floor of the mouth and tongue requires a 
closer follow-up compared with other histiotypes. ACC of the 
tongue is rare and an early diagnosis is important as these are 
slow-growing tumors with diffuse invasion. Among ACC of 
the head and neck region, the tongue is the site of origin in 
3.4-17.1% of the cases. A study by Luna-Ortiz et al (11) demon-
strated that among their 68 patients with a diagnosis of head 
and neck ACC, eight cases (seven female and one male) were 
found to exhibit ACC of the tongue (11.7% of all head and neck 
ACCs), six at the base and two in the mobile tongue (Table I). 
When located in the tongue, the clinical course is usually 
asymptomatic, with gradual submucosal tumoral growth, with 
a diagnostic delay estimated from 6 months to 8 years (11,13). 
In the presented case of the current study there was a diag-
nostic delay of ~8 months. The majority of tumors of the base 
of the tongue are in advanced stages at diagnosis, while tumors 
of the mobile tongue that produce more functional alterations 
are usually diagnosed at an earlier stage (5,11).
ACCs have been histologically graded on the basis of their 
solid component: Grade 1, no solid component; grade 2, <30% 
solid component; and grade 3, ≥30% solid component (14-16). 
The solid subtype presents the worst prognosis, with a survival of 
34% at 10 years, in contrast to 76% of the cribriform and 100% 
of the tubular subtypes, and is associated with recurrences, early 
distant metastases and a higher mortality rate (17). Other studies, 
however, did not found any correlation between microscopic 
appearance and prognosis (8). Franzén et al (14) reported that the 
prognosis is adversely effected by grade 3 histology (P=0.0001), 
DNA aneuploidy and an S-phase of ≥6% (P=0.0044) (14). 
Huang et al (18) observed a survival rate of 16.7 % after a 10-year 
treatment for cases where solid variable was observed and 47.4% 
for cribriform and tubular lesions. Norberg-Spaak et al (16) 
assessed mindbomb E3 ubiquitin protein ligase 1 (MIB1) posi-
tivity as an indicator of proliferation and found that the mean 
percentage of MIB1‑positive cells was significantly correlated 
with the histological grade and, that the chance of recurrence 
was significantly lower for patients with low‑MIB1 positivity.
The primary treatment objective in patients with ACC 
is local control, normal functionality and distant metastasis 
prevention and, for this purpose, early detection by the surgeon 
is required (3). Surgery is the cornerstone of treatment (5,11) 
and its extension depends on the size of the tumor. It may be 
conducted as a partial glossectomy, hemiglossectomy, total 
glossectomy with or without preservation of the larynx, or total 
glossectomy with or without reconstruction (11). A study by 
Soares et al (3) that was similar to the current study reported 
the case of a 64-year-old systemically healthy female patient 
who presented with a posterior tongue ACC. A hemiglossec-
tomy and cervical lymph node emptying at the third level were 
carried out, with post-surgical radiotherapy as an additional 
treatment. Compared with other malignant neoplasms, ACC is 
more difficult to fully remove, with frequently identified positive 
surgical margins (3). Radiotherapy is indicated when surgical 
margins are compromised; the use of adjuvant radiotherapy 
remains controversial (11). Certain studies administered adjuvant 
radiotherapy following surgery in all patients regardless of the 
margin status, with an increase in the local control rate at 5 or 
10 years (19,20). However, another study considered radiotherapy 
only for advanced T stages and as adjuvant in the presence of 
positive microscopic margins (21). Chen et al (22) found that 
Table I. Cases of ACC of the base of the tongue reported by Luna-Ortiz et al (9).
Age,       Metastatic  Distant 
years Gender T N M Clinical stage Surgery lymph nodes metastases Follow-up
38 F 4 0 0 IVA Left hemiglossectomy No No Alive without
         disease after
         207 months
48 F ‑ ‑ ‑ Not classified due to Total glossectomy, total laryngectomy, No Bilateral Fatality with
     being a recurrence floor of mouth resection and   pulmonary disease after
      reconstruction with pectoral flap   84 months
64 F 2 1 0 III Hemiglossectomy, left base of tongue  Yes,  No Fatality without
      excision, supraomohyoid left neck lymph node  disease after
      dissection and reconstruction with conglomerate  84 months
      pectoral flap
40 F 4 0 X IVA Total glossectomy, floor of mouth  No Bilateral Fatality with
      resection and reconstruction with pectoral   pulmonary disease after
      flap   60 months
67 M 3 0 0 III Primary tumor resection, radical 2/39 No Fatality without
      right neck dissection   disease
63 F 3 0 0 III Did not accept treatment - - -
ACC, adenoid cystic carcinoma; T, tumor; N, node; M, metastasis; F, female; M (gender), male.
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the independent predictors of local recurrence were omission of 
postoperative radiotherapy (P=0.007), T4 disease (P=0.0001), 
perineural invasion (P=0.008) and major nerve involvement 
(P=0.02). Surgery and adjuvant radiotherapy [to doses in excess 
of 60 Gy, according to Chen et al (22)] offer the best chance of 
curing patients with resectable ACC of the head and neck. Certain 
patients with advanced, incompletely resectable disease can 
be treated with radiotherapy alone. Some minor salivary gland 
ACCs may be completely resected less often compared with 
those in the major salivary glands and have a lower probability 
of cure with radiotherapy alone (19). Comparison of the efficacy 
of radiotherapy alone vs. surgery and radiotherapy is effected by 
selection bias: Patients with early-stage lesions tend to undergo 
surgery, while those with advanced, unresectable cancers tend 
to be treated with radiotherapy alone (19). Miglianico et al (23) 
reported that the improvement in local-regional control could not 
result in a significant improvement in survival rates following 
surgery compared with combined modality therapy and that the 
lack of a survival advantage may be a result of the high rate of 
distant metastases. 
Certain studies advocate adjuvant chemotherapy in addi-
tion to radiotherapy alone or combined with surgery due to 
the high risk of hematogenous dissemination, however, there is 
no convincing evidence that adjuvant chemotherapy is benefi-
cial (24), as experience with adjuvant chemotherapy for patients 
with ACCs is limited (19). Concomitant chemo-radiotherapy is 
an alternative for patients with advanced disease or to preserve 
organs, but it is relatively inefficacious in treating ACC (11).
The probability of regional lymph node metastases in 
ACC of head and neck region is relatively low, ranging from 
6 to 10% (5,23,25-27), and one of the reasons may be that the 
two commonest sites for ACC, parotid and palate/maxilla, 
have low propensity for nodal spread (27). Min et al (5), in 
a retrospective study involving 616 patients with ACC of the 
head and neck region, reported that lesions involving the base 
of the tongue, the mobile tongue and the mouth floor were the 
three primary sites with the highest incidences of cervical 
lymph nodes metastasis (19.2, 17.6 and 15.3%, respectively). 
Primary tumor site and peri-tumoral lymphovascular inva-
sion were significantly associated with cervical lymph node 
metastasis. Levels Ib and II were the most frequently involved, 
with a reported incidence of 27 (43.5%) and 37 (59.6%) cases, 
respectively, while levels III and IV were affected only in 
14 cases (22.5%). The overall survival rate at 5 years was 
significantly lower (P=0.037) in patients with lymph node 
metastasis (48%), compared with those without lymph node 
metastasis (77%). The authors proposed that selected neck 
dissection is not necessary in the majority of cases of primary 
cN0 patients. In addition, for floor‑of‑mouth and tongue lesions, 
dissection should be considered in patients with cN0 neck 
and larger ACC in these sites with lymphovascular invasion. 
Furthermore, for primary or recurrent cN+ patients, the 
combined approach of radical surgery, including wide resec-
tion of the original tumor and radical neck dissection, followed 
by postoperative irradiation, is strongly recommended (5). A 
previous study has suggested that it would be prudent to elec-
tively treat the first echelon nodes, particularly in patients with 
primary tumors in sites rich in lymphatic vessels, including 
the base of the tongue and nasopharynx (4). In accordance 
with these studies, the present study performed an elective 
emptying of cervical lymph nodes at levels I-III ipsilateral to 
the tumor. Balamucki et al (19) found that the rates of neck 
control at 5 and 10 years were 95 and 89% following observa-
tion and 98 and 98% subsequent to elective nodal irradiation, 
performed for tumors located in primary sites rich in capillary 
lymphatics. Gomez et al (28) reported that their patients who 
received radiotherapy to the neck experienced 100% neck 
control, while four of 50 node-negative patients experienced a 
neck failure at a median 12.6 years after radiotherapy. 
ACC has a high propensity for perineural invasion (11,19), 
which indicates a worse prognosis, decreasing survival to 76% 
against 100% of those not presenting with it (17).
C-kit (CD-117), a tyrosine kinase receptor involved in 
the growth and development of normal tissues and in certain 
neoplasms, has been previously identified to be expressed in 
ACC (29). Luna-Ortiz et al (11) observed c-kit positivity in all 
their eight cases of ACC of the tongue, and it was also observed 
in the present case. Certain studies have considered the use of 
tyrosine kinase inhibitors, including imatinib mesylate, as an 
adjuvant and/or therapeutic tool in managing distant metastases. 
A study by Alcedo et al (30) identified favorable results in two 
cases of unresectable ACC treated with imatinib mesylate; one 
for recurrent disease and the other for a locally advanced tumor. 
However, it has been observed the progression of the disease 
during treatment with imatinib mesylate (31). Mutations in 
Table II. Local control rates: Review of the literature.
 Local control rates, %
 -----------------------------------------------------------------------------------------
 RT alone, Surgery alone, RT + surgery,
 years years years
Authors, year -------------------------- ------------------------------- ---------------------------
(ref) 5 10 5 10 5 10
Cowie et al, 37    86 
1984 (11)
Matsuba et al,    25  83
1984 (35)
Miglianico et al, 66  44  78 
1987 (23)
Balamucki et al, 55 36   88 84
2012 (19)
Table III. Survival: Review of the literature.
 RT alone, % RT + surgery, %
 ----------------------------- -------------------------------
Authors, year 5 10 5 10
(ref) years years years years
Overall survival
  Miglianico et al, 1987 (23) 79  72 
  Balamucki et al, 2012 (19) 56 37 75 57
Disease-free survival
  Miglianico et al, 1987 (23) 47  54 
  Balamucki et al, 2012 (19) 65 46 79 71
Distant metastasis-free survival
  Balamucki et al, 2012 (19) 80 76 72 62
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11 c-kit and 9 c-kit exons condition an 83.5 and 47.8% response 
to tyrosine kinase inhibitors, respectively, in contrast to patients 
with non-detectable c-kit mutations, who do not present an 
objective response (32). The relevance of c-kit expression is due 
to its potential role in direct treatment of non-resectable or meta-
static disease, although the use of imatinib mesylate remains 
controversial, which is also due to its high cost (11).
Other studies have revealed that a high proportion (85%) 
of ACCs stain positively for epidermal growth factor receptors 
(EGFR) and may respond to agents that act as EGFR inhibi-
tors (33).
ACC presents a poor prognosis and it is therefore necessary 
to carry out long-term follow-up (Tables II and III). It has been 
reported to be a recurrent disease following treatment, ranging 
from 19 to 51% (19,25) with a median time to recurrence of 
2.7 years (range, 0,3-20.2 years) (19). The incidence of ACC 
with distant metastasis, ranging from 31 to 50%, leads to a 
low long-term survival rate (5,11,23,25). The reported overall 
survival in ACC of the head and neck ranges from 51-56.5% and 
32.5-34% at 5 and 10 years, respectively (11,34). In conclusion, 
the current study presents a noteworthy case of c-kit positive 
posterior tongue ACC treated with surgery and adjuvant radio-
therapy. The cervical lymph nodes were also emptied ipsilateral 
to the tumor at levels I-III, as according to other studies the base 
of the tongue is a site rich in lymphatic vessels.
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